16 analysts have shared their evaluations of Gilead Sciences (NASDAQ:GILD) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Gilead Sciences (GILD) been one of those stocks this year? Let's take a ...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two ...

We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...

Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big biotech company announced its 2024 fourth-quarter and full-year ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates.

Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold to Buy. As of February 18, 2025, the average one-year price target for ...

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better. Headquartered in Foster City, CA, Gilead Sciences is a pioneer in developing drugs for the treatment of human ...

Gilead currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Just Released: Zacks Top 10 Stocks for 2025 Hurry – you can ...

Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Gilead Sciences Inc (Symbol: GILD) were yielding above the 3% mark based on its quarterly dividend ...

Deep-pocketed investors have adopted a bearish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at ...